课题基金 / 基金详情

Clinical Research Training For Studies of CVD in India

Clinical Research Training For Studies of CVD in India
印度心血管疾病研究临床研究培训
批准号:
6449951
负责人:
LARRY W MORELAND
金额:
$11.34万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-26 至 2004-04-30

项目摘要

项目成果

LARRY W MORELAND的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):冠心病患病率最高 世界上的疾病(CHD)和糖尿病出现在印度和南亚。 这些疾病目前是与以下疾病相关的最重要问题 这个民族的老龄化。阿拉巴马大学的研究人员 伯明翰和马德拉斯糖尿病研究基金会(MDRF) 已经开始合作解决这一重要的研究领域。MDRF 在进行大规模流行病学研究方面表现出非凡的能力 资源有限,调查人员接触有限 流行病学培训。然而,尽管他们取得了成就,但有一个 需要进一步培训才能增加基础?S的指挥能力 纵向流行病学研究和临床试验。目前的建议是, 响应RFA TW-01-003,将快速加速和增强现有 两个机构之间的合作,通过提供一个培训计划 MDRF实习生临床研究。为了完成培训,我们 将利用三大UAB资源。第一个是临床研究 培训计划(CRTP),这是申请的父拨款,具有 制定了短期和长期培训部分,在此基础上 目前的培训计划暂不公布。第二个资源是 心血管流行病学联合教研室 预防医学和公共卫生学院,包括 该地区全国公认的教育工作者。最后,约翰·J·斯帕克曼 国际健康教育中心将提供行政和 协调培训所需的先前国际培训专业知识 活动。UAB和Madras的印度合作者将拥有主要领导力 在培训和计划规划中的角色。四名学员将来UAB参加 长期培训导致临床研究MSPH(为 家长补助金),每个培训基于MDRF研究的一个特定领域 目标(流行病学、临床试验、生物统计学和遗传学)。二 一批批学员将来到UAB进行为期60小时的短期培训 CRTP版本和其他相关教育经验;后续行动 课程将在一年后在MDRF开设。区域培训将是 通过UAB和MDRF教员在印度授课的研讨会提供 与南亚动脉粥样硬化和血栓学会的协会。 计划中的计划将提供一个已经很出色的印度研究中心 拥有大量训练有素的临床研究人员。终极意义 这一项目的价值在于,它可能导致治疗和预防策略 世界上最大的冠心病高危人群,或者说占世界五分之一的人群?S 人口。
英文摘要
DESCRIPTION (provided by applicant): The highest rates of Coronary Heart Disease (CHD) and diabetes in the world are found in India and south Asia. These diseases presently represent the most important problems associated with aging in this ethnic group. Researchers at the University of Alabama at Birmingham (UAB) and the Madras Diabetes Research Foundation (MDRF) have already begun collaborating to address this vital area of research. The MDRF has shown remarkable abilities in carrying out large epidemiological studies with limited resources and investigators with limited exposure to epidemiological training. However, despite their accomplishments, there is a need for further training to increase the foundation?s abilities to conduct longitudinal epidemiological studies and clinical trials. The present proposal, in response to RFA TW-01-003, will rapidly accelerate and enhance the existing collaboration between the two institutions by providing a training program in clinical research for MDRF trainees. In order to accomplish the training, we will utilize three major UAB resources. The first is the Clinical Research Training Program (CRTP), the parent grant of the application, that has developed the short-term and long-term training components upon which the present training plan rests. The second resource is the expertise in cardiovascular epidemiology from the combined faculty of the Division of Preventive Medicine and the School of Public Health, including several nationally recognized educators in the area. Finally, the John J. Sparkman Center for International Health Education will provide the administrative and prior international training expertise needed to coordinate training activities. Indian collaborators at UAB and Madras will have major leadership roles in training and program planning. Four trainees will come to UAB for long-term training leading to a MSPH in Clinical Research (as developed for the parent grant), with each training in a specific area based on MDRF research objectives (epidemiology, clinical trials, biostatistics, and genetics). Two groups of trainees will come to UAB for short-term training involving a 60 hour version of the CRTP and other relevant educational experiences; a follow-up course to be given at the MDRF one year later. Regional training will be provided through workshops taught in India by UAB and MDRF faculty in association with the South Asian Society for Atherosclerosis and Thrombosis. The planned program will provide an already outstanding Indian research center with a critical mass of trained clinical researchers. The ultimate significance of this project is that it may lead to treatment and prevention strategies for the largest group at risk for CHD in the world, or one-fifth of the world?s population.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UPITT Rheumatoid Arthritis Combined Center (UPITT RACC)
ANTIBODIES AND MARKERS OF DISEASE ACTIVITY IN PATIENTS WITH AUTOIMMUNE DISEASES
Rheumatoid Arthritis Induction Trial (RAITMAT)
AUTOIMMUNE BIOMARKERS COLLABORATIVE NETWORK
海外基金